These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18317677)

  • 1. Combination therapies in multiple sclerosis.
    Gold R
    J Neurol; 2008 Mar; 255 Suppl 1():51-60. PubMed ID: 18317677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New therapeutic agents in the management of multiple sclerosis].
    Besson G; Carpentier F
    Presse Med; 1998 Dec; 27(39):2032-5. PubMed ID: 9893694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glatiramer acetate for the treatment of multiple sclerosis.
    Wolinsky JS
    Expert Opin Pharmacother; 2004 Apr; 5(4):875-91. PubMed ID: 15102570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidance on new therapies in multiple sclerosis patients.
    Gonsette RE
    Lancet; 1996 Jul; 348(9020):136. PubMed ID: 8676708
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of multiple sclerosis and related disorders: what's new in the past 2 years?
    Noseworthy JH
    Clin Neuropharmacol; 2003; 26(1):28-37. PubMed ID: 12567162
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunologic therapy for relapsing-remitting multiple sclerosis.
    MacLean HJ; Freedman MS
    Curr Neurol Neurosci Rep; 2001 May; 1(3):277-85. PubMed ID: 11898530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon beta and glatiramer acetate therapy.
    McGraw CA; Lublin FD
    Neurotherapeutics; 2013 Jan; 10(1):2-18. PubMed ID: 23264098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer versus older treatments for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B; Cohen JA
    Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic therapy for secondary and primary progressive multiple sclerosis.
    Myers LW
    Curr Neurol Neurosci Rep; 2001 May; 1(3):286-93. PubMed ID: 11898531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
    Dhib-Jalbut S
    Neurology; 2002 Apr; 58(8 Suppl 4):S3-9. PubMed ID: 11971121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multiple sclerosis (MS), an inflammatory or degenerative disease?].
    Confavreux C; Vukusic S
    Presse Med; 2004 Feb; 33(3):151-2. PubMed ID: 15029024
    [No Abstract]   [Full Text] [Related]  

  • 19. [New approaches in research of therapy of multiple sclerosis].
    Hemmer B; Cepok S; Nessler S; Sommer N
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():23-8. PubMed ID: 11603112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why treat early multiple sclerosis patients?
    Comi G
    Curr Opin Neurol; 2000 Jun; 13(3):235-40. PubMed ID: 10871245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.